5 completed. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow mFOLFIRINOX: new trials by email Literature Review of mFOLFIRINOX trials Research Report on mFOLFIRINOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer Fluzoparib, Fluzoparib placebo, mFOLFIRINOX - Advanced Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 39 | 2020-01-21 | 2024-08-16 |
| Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) mFolfirinox, Chemoradiotherapy, surgery - Pancreatic Carcinoma | Phase 2 | Completed | Institut de Cancérologie de Lorraine | 130 | 2016-10-13 | 2026-09-01 |
| Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer mFOLFIRINOX, Ramucirumab, Placebo - Pancreatic Cancer | Phase 2 | Completed | Walid Shaib, MD | 84 | 2016-09-11 | 2025-01-01 |
| Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours GEMCIS, mFolfirinox - Bile Duct Cancer | Phase 2 / Phase 3 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 191 | 2015-12-15 | 2022-02-24 |
| mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer mFOLFIRINOX - Metastatic Pancreatic Cancer | Phase 2 | Completed | Yuhong Li | 40 | 2013-02-01 | 2023-02-16 |
Pancreatic Neoplasms (3) · Bile Duct Neoplasms (1)
Centre Hospitalier Universitaire de Saint Etienne (1) · Institut de Cancérologie de Lorraine (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Walid Shaib, MD (1) · Yuhong Li (1)
China (2) · France (2) · United States (1)
Jean-Marc Phelip, PhD (1) · Li Yuhong, MD (1) · Walid Shaib, MD (1) · Xianjun Yu, M.D. (1)
PMID 31068222, PMID 34662180, PMID 37268519, PMID 39232761
2014 (1), 2015 (1)